bortezomib,lenalidomide,dexamethasone,daratumumab
janssen,takeda
dr. douglas sborov detailed the results of the griffin ph-2 trial. key findings support the use of drvd induction and d+ r for maintenance as a potential soc in asct-eligible ndmm pts. ph- 3 trial results will offer greater clarity in determining future applications. #ims2022 
To cure myeloma by fostering research, education and excellence in clinical care worldwide.